FFFangyoumin Feng

Fangyoumin Feng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fangyoumin Feng has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Hong Li

    CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China

    3 shared publications
  • Bihan Shen

    Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China

    2 shared publications
  • Liangxiao Ma

    Bio-Med Big Data Center, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences , Shanghai 200031

    2 shared publications
  • Xueliang Li

    Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai China

    2 shared publications
  • Bihan Shen

    CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China

    1 shared publication
  • Kunshi Li

    CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences , Shanghai 200031

    1 shared publication

Latest Publications

  • Open Access

    Dual-view jointly learning improves personalized drug synergy prediction

    by Xueliang Li, Bihan Shen, Fangyoumin Feng, Kunshi Li, Liangxiao Ma, Hong Li

    Motivation: Accurate and robust estimation of the synergistic drug combination is important for precision medicine. Although some computational methods have been developed, some predictions are still unreliable especially for the cross-dataset predictions, due to the complex mechanism of drug combinations and heterogeneity of cancer samples. Results: We have proposed JointSyn that utilizes dual-view jointly learning to predict sample-specific effects of drug combination from drug and cell features. JointSyn outperforms existing state-of-the-art methods in predictive accuracy and robustness across various benchmarks. Each view of JointSyn captures drug synergy-related characteristics and make complementary contributes to the final accurate prediction of drug combination. Moreover, JointSyn with fine-tuning improves its generalization ability to predict a novel drug combination or cancer sample only using a small number of experimental measurements. We also used JointSyn to generate an estimated atlas of drug synergy for pan-cancer and explored the differential pattern among cancers. These results demonstrate the potential of JointSyn to predict drug synergy, supporting the development of personalized combinatorial therapies.

  • Open Access

    Dual-view jointly learning improves personalized drug synergy prediction

    by Xueliang Li, Bihan Shen, Fangyoumin Feng, Kunshi Li, Zhixuan Tang, Liangxiao Ma, Hong Li

    Motivation: Accurate and robust estimation of the synergistic drug combination is important for medicine precision. Although some computational methods have been developed, some predictions are still unreliable especially for the cross-dataset predictions, due to the complex mechanism of drug combinations and heterogeneity of cancer samples. Results: We have proposed JointSyn that utilizes dual-view jointly learning to predict sample-specific effects of drug combination from drug and cell features. JointSyn outperforms existing state-of-the-art methods in predictive accuracy and robustness across various benchmarks. Each view of JointSyn captures drug synergy-related characteristics and makes complementary contributes to the final prediction of the drug combination. Moreover, JointSyn with fine-tuning improves its generalization ability to predict a novel drug combination or cancer sample using a small number of experimental measurements. We also used JointSyn to generate an estimated atlas of drug synergy for pan-cancer and explored the differential pattern among cancers. These results demonstrate the potential of JointSyn to predict drug synergy, supporting the development of personalized combinatorial therapies. Availability and implementation: Source code and data are available at https://github.com/LiHongCSBLab/JointSyn.


  • Open Access

    Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine

    by Fangyoumin Feng, Bihan Shen, Xiaoqin Mou, Yixue Li, Hong Li